Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Patrick Boisseau Elected Chairman of the ETPN

Published: Monday, March 25, 2013
Last Updated: Monday, March 25, 2013
Bookmark and Share
Program will focus on building a structure that speeds innovations’ time to market and patients, while keeping Europe’s nanomed IP at home.

CEA-Leti has announced that Patrick Boisseau, the head of Leti’s nanomedicine program, has been elected chairman of the European Technology Platform - Nanomedicine (ETPN), a joint initiative between industry, academia, clinicians and the European Commission to help build a profitable nanomedicine sector in Europe.

Nanomedicine development in Europe and globally has evolved from fundamental research in the first decade of this century to development of products, patents, clinical trials and regulatory approval.

Most of the innovation in Europe is occurring in research labs and small to midsize enterprises (SMEs), including start-ups that have spun off from universities and research institutes.

These SMEs typically conduct preclinical and early clinical proofs of concept with a goal of transferring the clinical development to large companies that have the financial resources and expertise to complete the costly and sometimes lengthy clinical trials and regulatory approval.

But optimism about nanomed’s potential impact on healthcare and for creating value and jobs has created intense global competition for nanomed IP and new technologies.

Boisseau said two of his primary goals during his two-year term as chairman of ETPN are keeping the nanomed innovation that is underway at many European facilities and SMEs in Europe and to help build a nanomedicine sector that can compete strongly with Asia and the U.S.

“One key way to do that is to organize a supply chain of SMEs to facilitate the transfer of innovation and technology to large companies and make these technologies available to patients as soon as possible,” he said.

Boisseau continued, “It also will require us to build key infrastructure in Europe, such as an EU nanotechnology characterization lab or a network of good manufacturing practices sites for medical nanomaterials. This initiative also will be a good opportunity for leading European institutes like KTH, EPFL, Helmholtz Fondation, Tecnalia, Fraunhofer, SINTEF and Leti to expand their nanomed partnerships with both SMEs and large companies.”

Boisseau has chaired the ETPN working group on nano diagnostics since the ETPN was formed in 2005.

“Nanomedicine, which is a key part of Leti’s focus on emerging healthcare technologies, holds tremendous potential to improve healthcare delivery for people all over the world,” said Leti CEO Laurent Malier.

Malier continued, “Leti’s focus on creating innovation in this field and transferring it to industry strongly supports the European Technology Platform - Nanomedicine’s mission, and Patrick Boisseau brings a practical and forward-looking perspective to his role as chairman of ETPN.”

In the same election, Dr. Laurent Levy, CEO of Nanobiotix, was elected vice chairman of ETPN. He represents SMEs on the platform’s executive board.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Leti and Diabeloop Project Aims at Developing Artificial Pancreas
Artificial pancreas will automatically deliver the appropriate dose of insulin to patients.
Saturday, July 25, 2015
Leti Announces Launch of First European Nanomedicine Characterization Laboratory
Project combines expertise of 9 partners in 8 countries to foster nanomedicine innovation and facilitate regulatory approval.
Tuesday, July 07, 2015
Scientific News
Investigational Malaria Vaccine Protects Healthy U.S. Adults
Researchers at NIH have found that the malaria vaccine protected a small number of healthy, malaria-naïve adults in the U.S. from infection for more than one year after immunization.
AACR 2016: Cancer Immunotherapy and Beyond
At this year's meeting there was a palpable buzz around subjects ranging from microbiomics to the tumor microenvironment and cancer vaccines, big data to in vitro and in vivo modeling and drug delivery (to name just a few).
New Database for Sharing MS Clinical Trial Data
A new database containing nearly 2500 patient records from the placebo arms of nine multiple sclerosis (MS) clinical trials is now available for research by qualified investigators.
Study Finds Factors That May Influence Influenza Vaccine Effectiveness
Researchers at NIH have suggested that the long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited.
BMS’s Opdivo Clinical Trial Shows Promise
Safety profile of the combination regimen from CheckMate -069 was consistent with previously reported studies and adverse events were managed using established safety algorithms.
Treatment of Common Prostate Cancer
Researchers at UTSW have found that the prostate cancer treatments suppress immune response and may promote relapse.
Cancer Drug Could Treat Blood Vessel Deformities
A drug currently being trialled in cancer patients could also be used to treat an often incurable condition that can cause painful blood vessel overgrowths inside the skin.
Structure of Crucial Enzyme Identified
Researchers at UTSW have determined the atomic structure of an enzyme that plays an essential role in cell division and better treatment of cancer.
New Immunotherapy Trial for Type 1 Diabetes
The search for a treatment for Type 1 diabetes (T1D) - which affects over 400,000 people in the UK – will be stepped up with the start of a new phase one clinical trial at Guy’s Hospital in London.
Recruitment of First Patient in Clinical Study
Company has announced recruitment of first patient in clinical study assessing Visco-ease with Beatson Cancer Centre for the treatment of RIX.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!